5月13日，ST葫芦娃举办2024年度业绩说明会。会上管理层介绍，公司2024年财务报表的审计报告意见类型为保留意 见。公司2024年年报审计意见中未涉及关联方资金占用问题，也未涉及大股东利益输送及回扣等问题。 此外，公司已成立了专项整改工作小组，由公司董事长担任组长，组织各部门做好整改工作，指定公司财务总监、董 事会秘书担任沟通联络人，及时将整改情况向海南证监局汇报。 公司董事、监事、高级管理人员以及各相关部门负责人，本着实事求是的原则，结合公司实际情况，尽快完成整改， 申请撤销ST。 公司截至上年末应收账款前十大客户中，有6家客户有期后回款，其余4家客户由于正在授信账期内，所以暂无期后回 款；公司制定了严格的授信管理政策，并按授信政策执行管控，确保公司应收账款按期有效回笼。 管理层还在交流中回复，公司董事会已经制定了详细的工作规划，致力于提升公司经营效益。公司将持续聚焦儿童健 康消费市场优势品类，搭建从精准研发到快速上市的体系，努力塑造"葫芦娃=儿童健康专家"的品牌心智。 以"市场"需求为导向，加大对葫芦娃产品的市场覆盖，分类制定不同属性的产品的渠道和终端覆盖策略。加快大健康 新零售平台的搭建，依托海南自 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2025-035 海南葫芦娃药业集团股份有限公司 关于参加"2024年度海南辖区上市公司 业绩说明会暨投资者集体接待日"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让投资者更准确地读懂年度报告、更 全面地了解上市公司，切实提高上市公司透明度和治理水平，海南证监局将与深圳市全景网络有限公 司、海南上市公司协会联合举办"2024年度海南辖区上市公司业绩说明会暨投资者集体接待日"活动，活 动时间为2025年5月13日14:00-17:00，平台登陆地址为：https://rs.p5w.net。 届时，海南葫芦娃药业集团股份有限公司（以下简称"公司"）主要高管人员将参加本次活动，通过网络 在线交流形式，就公司2024年年报披露、财务数据、公司治理、内部控制、发展战略、经营状况、现金 分红、重大事项、可持续发展等投资者所关心的问题，与投资者进行"一对多"形式的沟通与交流。欢迎 广大投资者踊跃参与。 特此公告。 海南葫 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2025-034 海南葫芦娃药业集团股份有限公司 股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 海南葫芦娃药业集团股份有限公司（以下简称"公司"）股票于 2025 年 4 月 30 日至 5 月 7 日连续 3 个交易日内收盘价格跌幅偏离值累计超过 12%。 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 经公司自查，并向公司控股股东和实际控制人书面核实，截至本公告披 露日，公司不存在应披露而未披露的重大事项。 公司股票交易于2025年4月30日至5月7日连续3个交易日内收盘价格跌幅偏 离值累计超过12%。根据《上海证券交易所交易规则》的有关规定，属于股票交 易异常波动情形。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，公司目前生产经营活动正常，主营业务未发生重大变化。 1 （二）重大事项情况 经公司自查，并向公司控股股东海南葫芦娃投资发展有限公司及实际控制人 函证核实：截至本公告披露日，除了在 ...

股票交易异常波动征询函的回函 海南葫芦娃药业集团股份有限公司: (以下无正文,下接签署页) 贵公司于 2025 年 5 月 7 日发来的《海南葫芦娃药业集团股份有 限公司股票交易异常波动的征询函》已收悉,作为贵公司的实际控制 人,经自查,现就相关情况回函如下: (此页无正文,为《海南葫芦娃药业集团股份有限公司股票交易异常 波动的征询函的回函》签署页） 实际控制人: 2025年5月7日 1、在贵公司股票于 2025年 4 月 30 日至 5 月 7 日连续 3 个交易 日内收盘价格跌幅偏离值累计超过 12%期间,本人及一致行动人不存 在买卖贵公司股票的情况。 2、除责公司已披露事项外,本人不存在涉及贵公司的应披露而 未披露的重大信息,包括但不限于重大资产重组、发行股份、重大交 易类事项、业务重组、股份回购、股权激励、破产重整、重大业务合 作、引进战略投资者等重大事项。 特此回函。 股票交易异常波动征询函的回函 海南葫芦娃药业集团股份有限公司: 贵公司于 2025年5月7日发来的《海南葫芦娃药业集团股份有 限公司股票交易异常波动的征询函》已收悉,作为贵公司的控股股东, 经自查,现就相关情况回函如下: 1、在贵公司 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为推动辖区上市公司进一步建立董事会与投资者的良好沟通机制，让 投资者更准确地读懂年度报告、更全面地了解上市公司，切实提高上市公 司透明度和治理水平，海南证监局将与深圳市全景网络有限公司、海南上 市公司协会联合举办"2024 年度海南辖区上市公司业绩说明会暨投资者集 体接待日"活动，活动时间为 2025 年 5 月 13 日 14:00-17:00，平台登陆地 址为：https://rs.p5w.net。 证券代码：605199 证券简称：葫芦娃 公告编号：2025-035 海南葫芦娃药业集团股份有限公司 关于参加"2024 年度海南辖区上市公司 业绩说明会暨投资者集体接待日"的公告 特此公告。 海南葫芦娃药业集团股份有限公司董事会 2025 年 5 月 7 日 届时，海南葫芦娃药业集团股份有限公司（以下简称"公司"）主要 高管人员将参加本次活动，通过网络在线交流形式，就公司 2024 年年报披 露、财务数据、公司治理、内部控制、发展战略、经营状况、现金分红、 重大事项、可持续发展 ...

海南葫芦娃药业集团股份有限公司 2024 年度股东大会 会议资料 2025 年 5 月 | | | | 2024 | 年度股东大会会议议程 2 | | | --- | --- | --- | | 2024 | 年度股东大会会议须知 4 | | | 议案一: | 关于公司 年度董事会工作报告的议案 5 | 2024 | | 议案二: | 关于公司 年度监事会工作报告的议案 12 | 2024 | | 议案三: | 关于公司 年度报告及其摘要的议案 15 | 2024 | | 议案四: | 关于公司 年度财务决算报告的议案 16 | 2024 | | 议案五: | 关于 2024 年度拟不进行利润分配的议案 20 | | | 议案六: | 关于确认董事 2024 年度薪酬及 2025 年度薪酬方案的议案 21 | | | 议案七: | 关于确认监事 2024 年度薪酬及 2025 年度薪酬方案的议案 22 | | | 议案八: | 关于公司向金融机构申请 2025 年度综合授信额度及融资租赁、保理暨 | | | | 提供相应担保额度预计的议案 23 | | | 2024 | 年度独立董事述职报告（刘秋云） 28 ...

Core Insights - The company reported a significant decline in revenue and increased losses for the year 2024, indicating challenges in its business operations [1][2] Financial Performance - The company achieved a revenue of 1.414 billion yuan in 2024, a year-on-year decrease of 21.26% [1] - The net loss attributable to shareholders was 274 million yuan, an increase of 2629.23% year-on-year [1] - The adjusted net loss was 325 million yuan, expanding by 2250% compared to the previous year [1] - Basic earnings per share were -0.69 yuan, and the weighted average return on equity dropped to -31.66% [1] Revenue Breakdown - Revenue from respiratory system drugs was 989 million yuan, down 10.17% year-on-year, accounting for 70% of total revenue [2] - Revenue from digestive system drugs plummeted by 56.94% to 146 million yuan [2] - The company launched a new nutritional supplement, the compound lysine granules, and has received approval for seven health product varieties [2] R&D and Investment - R&D expenses increased by 58.63% year-on-year to 250 million yuan, representing 17.65% of total revenue [2] - The company added 12 new drug approvals and has seven Class I traditional Chinese medicine innovations in clinical stages, with three in Phase III trials [2] - The company is focusing on child-friendly formulations, including nebulized inhalation solutions and oral dissolving films [2] Asset and Financial Management - Fixed assets surged by 192.28% to 1.124 billion yuan, attributed to the launch of the Meian Children's Medicine intelligent manufacturing base [2] - Construction in progress decreased by 71.05% to 253 million yuan [2] - Cash and cash equivalents fell by 51.35% to 254 million yuan, indicating pressure on accounts receivable turnover [2] - Financial expenses increased by 74.36% due to the capitalization of interest expenses after project completion [2]

Core Insights - A-share listed companies demonstrated strong resilience in 2024, with total operating revenue reaching 62.33 trillion yuan, a year-on-year increase of 0.57%, and net profit attributable to shareholders of 5.06 trillion yuan, up 1.05% [1][2] - The growth was primarily driven by advancements in artificial intelligence (AI) technology, which significantly boosted demand in sectors such as GPU, PCB, and storage chips [2][3] - Despite overall growth, non-financial companies faced challenges, with a slight decline in revenue and a notable drop in net profit [1][3] Financial Performance - Among the 5402 listed companies, 4029 reported positive earnings, with 548 companies achieving over 100% growth in net profit [2] - The chemical company Zhengdan achieved a remarkable 119-fold increase in net profit, driven by soaring TMA prices due to supply-demand imbalances [2][3] - The semiconductor sector saw significant profit increases, with companies like Zhaoyi Innovation and Weir Shares reporting net profit growth of 584.21% and 498.11%, respectively [3] Sector Analysis - The AI sector is identified as a key growth driver, with companies in the GPU, PCB, and optical module industries experiencing substantial performance improvements [2][3] - The consumer electronics market is also rebounding, with a reported 5.6% year-on-year increase in smartphone shipments in China [3][4] International Expansion - A total of 3653 listed companies reported overseas revenue of 9.43 trillion yuan, accounting for approximately 20% of their total revenue [6][7] - Companies like Luxshare Precision and BYD achieved over 100 billion yuan in overseas revenue, with notable growth in emerging markets [6][7] - The internationalization strategies include local market investments and partnerships, particularly in Africa and the Middle East [7][8] Challenges and Losses - Despite overall positive performance, 124 companies reported net losses exceeding 1 billion yuan, with the real estate sector being particularly affected [9][10] - Vanke A led the loss rankings with a staggering 494.78 billion yuan loss, highlighting the difficulties faced in the real estate market [9][10] - The energy sector, including solar and lithium companies, also reported significant losses due to overcapacity and intensified competition [10] Regulatory Environment - The introduction of stricter delisting regulations is expected to normalize the delisting process, with 52 companies delisted in 2024 [11][12] - New rules include higher thresholds for financial delisting criteria, aiming to enhance market stability and protect investor interests [11][12]

Core Viewpoint - The company HuLuWa (605199.SH) has reported significant financial issues, including major internal control deficiencies, leading to a substantial decline in revenue and profits for 2024 [1][2][7]. Financial Performance - In 2024, HuLuWa achieved revenue of 1.414 billion yuan, a year-on-year decrease of 21.26% [4]. - The net profit attributable to shareholders was a loss of 274 million yuan, a year-on-year decline of 2629.23% [4]. - The net profit after deducting non-recurring items was a loss of 325 million yuan, down 2250.82% year-on-year [4]. - Cumulatively, the losses for 2023 and 2024 reached approximately 339 million yuan [4]. Product Performance - Among the top ten products, only the sales volume of Qiangli Pipa Lu increased, while the other nine products experienced a decline in sales [5]. - Notably, sales volumes for key products such as Changyanning Capsules and Compound Cold Medicine Granules dropped significantly, with reductions of 59.1% and 44.1% respectively [5]. Internal Control Issues - The auditing firm issued a negative opinion on HuLuWa's internal control audit report, indicating significant deficiencies [6][8]. - The company faced administrative regulatory measures from the Hainan Securities Regulatory Bureau due to inaccuracies in financial disclosures [2][7]. - The internal control deficiencies were linked to improper approval processes for significant transactions, raising concerns about the company's financial reporting integrity [8]. Stock Market Impact - Following the negative audit report, HuLuWa's stock will be subject to risk warnings, changing its trading name to "ST HuLuWa" starting April 30 [2][8]. - As of April 28, the stock closed at 13.06 yuan per share, with a total market capitalization of 5.225 billion yuan [8].

Core Viewpoint - Hainan Huhuwawa Pharmaceutical Group Co., Ltd. faces significant internal control issues, leading to a negative audit opinion and a stock trading suspension, with a change in stock abbreviation to "ST Huhuwawa" starting April 30, 2025 [1][3][5] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.414 billion yuan, a year-on-year decrease of 21.26%, and a net profit attributable to shareholders of -274 million yuan, a staggering decline of 2629.23% [10] - In the first quarter of 2025, the company achieved a revenue of 337 million yuan, down 28.42% year-on-year, with a net profit of approximately 24.35 million yuan, a decrease of 11.23% [10] Internal Control Issues - The audit report from Lixin Certified Public Accountants highlighted three major areas of concern regarding internal controls, including the lack of complete financial data related to restated financial statements and issues with accounts receivable from key clients [3][5] - The company has been criticized for significant deficiencies in its internal control over financial reporting, resulting in a negative opinion from the auditors [5] Management Changes - The company's general manager, Zhang Mingrui, resigned for personal reasons less than two months after taking office, marking a period of instability in leadership [2][6] - This resignation follows the earlier departure of Liu Jingping from the general manager position, who remains as chairman and has been a key figure in the company since its inception [7][8] Related Transactions - In 2024, the company purchased eight R&D projects from Hainan Zhongwang Medical Technology Development Co., Ltd. for 42.0537 million yuan, raising concerns due to familial ties between the company's actual controller and the legal representative of the vendor [4]